Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
New regional hub strengthens presence in a key market and enhances service delivery for corporate healthcare clients
While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Move comes amid rising regulatory pressures
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pharma giant targets new standards of care
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Subscribe To Our Newsletter & Stay Updated
